TLR3 and breast carcinoma: The study of Jia et al. not only illustrated an enrichment of CSCs in breast cancer upon TLR3 stimulation, but these CSC-like cells appeared to be more resistant to the common chemotherapeutic drug, such as paclitaxel and doxorubicin [58].